Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Ipatasertib (dihydrochloride)

Ipatasertib dihydrochloride (GDC-0068 dihydrochloride) is a highly selective and ATP-competitive pan-Akt inhibitor with IC50s of 5, 18 and 8 nM for Akt1, Akt2 and Akt3, respectively.

Product Specifications

CAS Number

[1396257-94-5]

Product Name Alternative

GDC-0068 (dihydrochloride) ; RG-7440 (dihydrochloride)

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Akt; Organoid

Type

Reference compound

Related Pathways

PI3K/Akt/mTOR; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/GDC-0068-dihydrochloride.html

Purity

99.27

Solubility

DMSO : 100 mg/mL (ultrasonic) |H2O : ≥ 41 mg/mL

Smiles

ClC1=CC=C([C@@H](CNC(C)C)C(N2CCN(C3=C([C@H](C)C[C@H]4O)C4=NC=N3)CC2)=O)C=C1.[H]Cl.[H]Cl

Molecular Formula

C24H34Cl3N5O2

Molecular Weight

530.92

Precautions

H315, H319, H335

References & Citations

[1]Blake JF, et al. Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors. J Med Chem. 2012 Sep 27;55 (18) :8110-27.|[2]Lin J, et al. Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models. Clin Cancer Res. 2013 Apr 1;19 (7) :1760-72.

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

Phase 3

Isoform

Akt1; Akt2; Akt3

Citation 01

Cell Rep. 2021 Feb 16;34 (7) :108744.|Mol Cell. 2020 Sep 17;79 (6) :1008-1023.e4.|Mol Cell. 2019 Jan 3;73 (1) :22-35.e6.|Ren Fail. 2025 Dec;47 (1) :2580064.|Biochem Biophys Res Commun. 2025 Jun 12:776:152203.|Biochem Pharmacol. 2020 Oct;180:114145.|Biomaterials. 2024 Mar:305:122462.|Biomed Chromatogr. 2020 Oct;34 (10) :e4920.|Biomed Chromatogr. 2020 Oct;34 (10) :e4923.|bioRxiv. 2024 August 18.|bioRxiv. 2024 August 26.|bioRxiv. 2024 Jan 16.|bioRxiv. 2024 September 07.|bioRxiv. 2025 March 20.|bioRxiv. 2025 May 4:2025.04.29.651320.|Blood. 2023 Sep 14;142 (11) :973-988.|Br J Cancer. 2025 Sep 4.|Cancer Immunol Immunother. 2020 Nov;69 (11) :2259-2273.|Cancer Res. 2021 May 1;81 (9) :2470-2480.|Cancers (Basel) . 2023 Nov 14;15 (22) :5407.|Cell Metab. 2021 Nov 2;33 (11) :2247-2259.e6.|Cold Spring Harb Mol Case Stud. 2022 Jan 10;8 (1) :a006140.|Department of Laboratory Medicine, Laboratory of Hematology of the Radboudumc and Radboud Institute for Molecular Life Sciences in Nijmegen, The Netherlands.2019 Oct.|Elife. 2020 Dec 7;9:e61405.|EMBO Mol Med. 2025 Feb;17 (2) :336-364.|EMBO Rep. 2020 Mar 4;21 (3) :e49129.|Front Oncol. 2021 Nov 24:11:766298.|Haematologica. 2020 Mar;105 (3) :661-673.|Harvard Medical School LINCS LIBRARY|Int J Biol Sci. 2025 Jan 27;21 (4) :1545-1565. |Int J Cancer. 2021 Sep 1;149 (5) :1137-1149.|Int J Hyperthermia. 2024 Feb 13;41 (1) :2310017.|J Cell Biochem. 2024 Aug;125 (8) :e30613.|Life Sci. 2020 Sep 1;256:117955.|Life Sci. 2021 Jul 15:277:119520.|Mol Cancer Ther. 2024 Oct 1;23 (10) :1404-1417.|Mol Oncol. 2024 Mar;18 (3) :726-742.|Mol Oncol. 2025 Jul 13.|Nat Cell Biol. 2025 Jan;27 (1) :73-86.|Nat Chem Biol. 2025 Aug;21 (8) :1194-1204.|Nat Commun. 2024 Dec 12;15 (1) :10476.|Nat Commun. 2025 Feb 25;16 (1) :1774.|Oncogene. 2025 Sep;44 (34) :3142-3148.|Oncoimmunology. 2018 Aug 6;7 (10) :e1488565. |Oncol Rep. 2018 Aug;40 (2) :635-646. |Oncotarget. 2016 May 17;7 (20) :29131-42. |Oncotargets Ther. 2020 Aug 18;13:8197-8208.|Oxid Med Cell Longev. 2021 Jan 12;2021:3010548.|Patent. US20220313694A1.|Preprints. 2025 Nov 18.|Research Square Preprint. 2024 Nov 26.|Sci Adv. 2023 Mar 22;9 (12) :eadd5028.|Sci Adv. 2025 Apr 25;11 (17) :eads6385.|Sci Rep. 2025 Aug 17;15 (1) :30048.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|Skelet Muscle. 2021 Mar 15;11 (1) :6.|SSRN. 2023 Jun 20.|Steroids. 2025 Sep 25:223:109692.

Available Sizes

More Discoveries

Explore Other Products

Browse additional items from our catalog

HMPV M2 / Protein M2-2 Polyclonal Antibody
ANT-12568-100ug 100 µg

HMPV M2 / Protein M2-2 Polyclonal Antibody

Sign In for Pricing
View Details
Lentiviral human POLR3K shRNA (UAS) - Lentiviral human POLR3K shRNA (UAS) plasmid
GTR15329410 1 Vial

Lentiviral human POLR3K shRNA (UAS) - Lentiviral human POLR3K shRNA (UAS) plasmid

Sign In for Pricing
View Details
Cand2 3'UTR Luciferase Stable Cell Line
TU201621 1.0 mL

Cand2 3'UTR Luciferase Stable Cell Line

Sign In for Pricing
View Details
Recombinant Human Protein FAM110B Protein, His, E.coli-100ug
QP6018-ec-100ug 100ug

Recombinant Human Protein FAM110B Protein, His, E.coli-100ug

Sign In for Pricing
View Details
IRF2 DNA-Binding ELISA Kit
TFE-7096 1 Kit

IRF2 DNA-Binding ELISA Kit

Sign In for Pricing
View Details
CRKL Protein (N-His, Human)
P502852 100 µg

CRKL Protein (N-His, Human)

Sign In for Pricing
View Details